Article may be outdated

This article is 3 days old. Some details may have changed since publication.

Headlinne
Sign inGet Headlinne
Drug Target Review·3 min read·hard

NTX-301 targets treatment-resistant AML via Hippo pathway in preclinical study

D
Drug Target Review
NTX-301 targets treatment-resistant AML via Hippo pathway in preclinical study
✦AI Summary

Researchers at MD Anderson Cancer Center have identified that the experimental drug NTX-301 shows promise in treating therapy-resistant acute myeloid leukaemia (AML). The drug works by activating the Hippo pathway, which helps suppress tumor growth and overcome drug resistance.

Why it mattersUnlock →

An investigational epigenetic therapy has shown encouraging results against treatment-resistant acute myeloid leukaemia (AML) in preclinical studies from The University of Texas MD Anderson Cancer Center .

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
Political bias analysisUnlock →
Read originalGet full access
✦

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in